FDA Clears LB2501 In Vivo CAR T Study
FDA cleared Legend Biotech’s IND for LB2501, an investigational single-infusion in vivo CAR-T therapy designed to generate dual CD19/CD20-targeting T cells inside the patient. Legend describes it as the first known dual-targeting in vivo…
